Risk Assessment, Genetic Counseling, and Genetic Testi

JAMA - Journal of the American Medical Association
322, 652
DOI: 10.1001/jama.2019.10987

Citation Report

#	Article	IF	Citations
1	Hereditary Cancer Evaluation in 2019â€"a Rapidly Evolving Landscape. JAMA Oncology, 2019, 5, 1539.	3.4	0
2	Maximizing the Outcomes of Breast Cancer Prevention. JAMA Internal Medicine, 2019, 179, 1621.	2.6	0
3	Blending Insights from Implementation Science and the Social Sciences to Mitigate Inequities in Screening for Hereditary Cancer Syndromes. International Journal of Environmental Research and Public Health, 2019, 16, 3899.	1.2	8
4	Regarding the Yin and Yang of Precision Cancer- Screening and Treatment: Are We Creating a Neglected Majority?. International Journal of Environmental Research and Public Health, 2019, 16, 4168.	1.2	5
6	Task force releases updated guidance on BRCA1/2 assessments. Pharmacy Today, 2019, 25, 4.	0.0	0
7	Hot Topic: Should all Women with Breast Cancer Undergo Genetic Testing?. Current Breast Cancer Reports, 2019, 11, 381-384.	0.5	1
8	Personalized breast cancer screening strategies: A systematic review and quality assessment. PLoS ONE, 2019, 14, e0226352.	1.1	38
9	Calling on Primary Care to Prevent BRCA-Related Cancers. Journal of General Internal Medicine, 2020, 35, 903-905.	1.3	2
10	BRCA1/BRCA2Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies. Annals of Laboratory Medicine, 2020, 40, 114-121.	1.2	67
11	From Genetic Testing to Treatment and Prevention of BRCA-Related Breast Cancer. Annals of Laboratory Medicine, 2020, 40, 99-100.	1.2	0
12	Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2020, 22, 681-685.	1.1	20
13	Genomic testing is best integrated into clinical practice when it is actionable. Personalized Medicine, 2020, 17, 5-8.	0.8	8
14	Implementing universal cancer screening programs can help sustain genomic medicine programs. Personalized Medicine, 2020, 17, 9-13.	0.8	1
15	DNA-Based Population Screening. JAMA - Journal of the American Medical Association, 2020, 323, 307.	3.8	31
16	Importance of family history and indications for genetic testing. Breast Journal, 2020, 26, 100-104.	0.4	13
17	A Pre-Testâ€"Post-Test Trial of a Breast Cancer Risk Report for Women in Their 40s. American Journal of Preventive Medicine, 2020, 59, 343-354.	1.6	4
18	Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer. Familial Cancer, 2021, 20, 181-187.	0.9	2
19	Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems. Cancers, 2020, 12, 1929.	1.7	49

#	Article	IF	Citations
20	Breast cancer risk assessment and management programs: A practical guide. Breast Journal, 2020, 26, 1556-1564.	0.4	7
21	Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology. JCO Global Oncology, 2020, 6, 991-1008.	0.8	9
22	The contemporary landscape of genetic testing and breast cancer: Emerging issues. Breast Journal, 2020, 26, 1549-1555.	0.4	6
23	Patient With Questions About Cancer Risk. Journal for Nurse Practitioners, 2020, 16, e109-e112.	0.4	0
24	Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women. JAMA - Journal of the American Medical Association, 2020, 324, 397.	3.8	0
25	Cancer Prevention and Screening for Older Adults: Part 2. Interventions to Prevent and Screen for Breast, Prostate, Cervical, Ovarian, and Endometrial Cancer. Journal of the American Geriatrics Society, 2020, 68, 2684-2691.	1.3	8
26	Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes. International Journal of Gynecological Cancer, 2020, 30, 1803-1810.	1.2	35
27	Breast cancer screening for women at high risk: review of current guidelines from leading specialty societies. Breast Cancer, 2021, 28, 1195-1211.	1.3	4
28	Integrating Personalized Medicine With Population Health Management. JAMA - Journal of the American Medical Association, 2020, 324, 631.	3.8	5
29	Parent of Origin Effects on Family Communication of Risk in BRCA+ Women: A Qualitative Investigation of Human Factors in Cascade Screening. Cancers, 2020, 12, 2316.	1.7	11
30	Strategies to enhance identification of hereditary breast cancer gene carriers. Expert Review of Molecular Diagnostics, 2020, 20, 861-865.	1.5	1
31	Implementing NGS-basedBRCAtumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations. Journal of Clinical Pathology, 2021, 74, 596-603.	1.0	10
32	Molecular Features and Clinical Management of Hereditary Gynecological Cancers. International Journal of Molecular Sciences, 2020, 21, 9504.	1.8	13
33	New perspectives on the genetic causes of diminished ovarian reserve and opportunities for genetic screening: systematic review and meta-analysis. F&S Reviews, 2020, 1, 1-15.	0.7	4
34	Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States. JAMA Network Open, 2020, 3, e2022874.	2.8	44
35	The Increasing Complexity of Preventive Services. Journal of Women's Health, 2020, 29, 748-749.	1.5	0
36	The Implementation Chasm Hindering Genome-informed Health Care. Journal of Law, Medicine and Ethics, 2020, 48, 119-125.	0.4	7
37	Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry. Scientific Reports, 2020, 10, 7669.	1.6	10

#	Article	IF	Citations
38	Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer. Current Breast Cancer Reports, 2020, 12, 125-131.	0.5	29
39	Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History. JAMA Network Open, 2020, 3, e203959.	2.8	75
40	Population-based Genetic Testing for Precision Prevention. Cancer Prevention Research, 2020, 13, 643-648.	0.7	20
41	Breast Cancer Risk Assessment. Mayo Clinic Proceedings, 2020, 95, 1268-1275.	1.4	12
42	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705.	12.5	178
43	Panel Testing for Hereditary Breast Cancer: More or Less?. Current Breast Cancer Reports, 2020, 12, 45-50.	0.5	0
44	Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 995.	3.8	26
45	Peridiagnostic and cascade cancer genetic testing. Nature Reviews Clinical Oncology, 2020, 17, 277-278.	12.5	2
46	Use of an Online Breast Cancer Risk Assessment and Patient Decision Aid in Primary Care Practices. Journal of Women's Health, 2020, 29, 763-769.	1.5	15
47	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. Journal of Clinical Oncology, 2020, 38, 1409-1418.	0.8	64
48	Subsequent Development of Epithelial Ovarian Cancer After Ovarian Surgery for Benign Ovarian Tumor: A Population-Based Cohort Study . Clinical Epidemiology, 2020, Volume 12, 637-649.	1.5	10
49	Implementation of interventions targeting the uptake of genetic testing services for breast cancer risk: protocol for a systematic review. BMJ Open, 2020, 10, e031727.	0.8	0
50	Updates in hereditary breast cancer genetic testing and practical high risk breast management in gene carriers. Seminars in Oncology, 2020, 47, 182-186.	0.8	5
51	Emerging Opportunity of Cascade Genetic Testing for Population-Wide Cancer Prevention and Control. Journal of Clinical Oncology, 2020, 38, 1371-1374.	0.8	18
52	Implications of the evidence for breast conservation therapy in BRCA-gene mutation carriers. British Journal of Radiology, 2020, 93, 20200038.	1.0	0
53	Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors. Genetics in Medicine, 2020, 22, 1088-1093.	1.1	10
54	Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1222-1245.	0.8	202
55	Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations. Cancer, 2020, 126, 693-693.	2.0	0

#	Article	IF	Citations
56	Recommendations Related to Genetic Testing for Breast Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 188.	3.8	0
57	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. Journal of Clinical Oncology, 2020, 38, 1398-1408.	0.8	60
58	Recommendations Related to Genetic Testing for Breast Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 187.	3.8	0
59	Recommendations Related to Genetic Testing for Breast Cancerâ€"Reply. JAMA - Journal of the American Medical Association, 2020, 323, 188.	3.8	1
60	Accurate and Scalable Construction of Polygenic Scores in Large Biobank Data Sets. American Journal of Human Genetics, 2020, 106, 679-693.	2.6	80
61	Direct-to-consumer misleading information on cancer risks calls for an urgent clarification of health genetic testing performed by commercial companies. European Journal of Cancer, 2020, 132, 100-103.	1.3	4
62	Genetic testing in male infertility â€“ reassessing screening thresholds. Current Opinion in Urology, 2020, 30, 317-323.	0.9	7
63	Population Screening for Inherited Predisposition to Breast and Ovarian Cancer. Annual Review of Genomics and Human Genetics, 2020, 21, 373-412.	2.5	31
64	A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. Cancer Prevention Research, 2020, 13, 429-442.	0.7	10
65	Genetic counselorsâ€™ perspectives on populationâ€based screening for BRCAâ€related hereditary breast and ovarian cancer and Lynch syndrome. Journal of Genetic Counseling, 2021, 30, 158-169.	0.9	8
66	Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. International Journal of Gynecological Cancer, 2021, 31, 352-359.	1.2	15
67	Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals. Familial Cancer, 2021, 20, 111-116.	0.9	5
68	Impact of Age, Race, and Socioeconomic Status on Women's Perceptions and Preferences Regarding Communication of Estimated Breast Cancer Risk. Academic Radiology, 2021, 28, 655-663.	1.3	4
69	â€œI think that a brief conversation from their provider can go a very long wayâ€: Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer. Supportive Care in Cancer, 2021, 29, 2663-2677.	1.0	7
70	The role of genomics in global cancer prevention. Nature Reviews Clinical Oncology, 2021, 18, 116-128.	12.5	22
71	Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study. Annals of Surgical Oncology, 2021, 28, 2219-2226.	0.7	7
72	Germline testing for homologous recombination repair genesâ€"opportunities and challenges. Genes Chromosomes and Cancer, 2021, 60, 332-343.	1.5	7
73	The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. Gynecologic Oncology, 2021, 160, 333-345.	0.6	40

#	Article	IF	Citations
74	Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants. Critical Reviews in Oncology/Hematology, 2021, 157, 103201.	2.0	26
75	A state-based approach to genomics for rare disease and population screening. Genetics in Medicine, 2021, 23, 777-781.	1.1	19
76	Training courses on hereditary breast and ovarian cancer to strengthen cross-sectoral care in underserved areas. Patient Education and Counseling, 2021, 104, 1431-1437.	1.0	2
77	Experiences and attitudes of hereditary cancer screening patients in a consumer directed testing model. Patient Education and Counseling, 2021, 104, 473-479.	1.0	2
78	Hereditary Gynecological Malignancy and Molecular Features. Current Human Cell Research and Applications, 2021, , 145-165.	0.1	0
79	Management of a Woman at Elevated Risk for Breast Cancer. , 2021, , 107-136.		0
80	Hereditary Cancer Counseling and Germline Genetic Testing. , 2021, , 305-317.		0
81	Timing and type of menopause and risk of cardiovascular disease. Menopause, 2021, 28, 477-479.	0.8	1
82	Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida. Journal of Community Genetics, 2021, 12, 415-429.	0.5	0
83	A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine, 2021, 384, 440-451.	13.9	414
84	Assessing Risk of Breast Cancer: A Review of Risk Prediction Models. Journal of Breast Imaging, 2021, 3, 144-155.	0.5	47
85	A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Menopause, 2021, 28, 748-755.	0.8	6
86	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. European Journal of Cancer, 2021, 146, 30-47.	1.3	81
87	Should the BCRA1/2-mutations healthy carriers be valid candidates for hematopoietic stem cell donation?. Hereditary Cancer in Clinical Practice, 2021, 19, 22.	0.6	0
88	Controversies in Hereditary Cancer Management. Obstetrics and Gynecology, 2021, 137, 941-955.	1.2	4
89	The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada. Cancers, 2021, 13, 1894.	1.7	8
91	Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and metaâ€•analysis. Clinical Genetics, 2021, 100, 119-131.	1.0	12
93	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. Gynecologic Oncology, 2021, 161, 521-526.	0.6	2

#	Article	IF	Citations
94	Clinical validity and utility of preconception expanded carrier screening for the management of reproductive genetic risk in IVF and general population. Human Reproduction, 2021, 36, 2050-2061.	0.4	27
95	A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study. Cancers, 2021, 13, 2729.	1.7	8
96	Cancer Progress and Priorities: Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 822-844.	1.1	47
97	Current status and future directions of U.S. genomic nursing health care policy. Nursing Outlook, 2021, 69, 471-488.	1.5	8
98	Inhibitor of DNA-binding family regulates the prognosis of ovarian cancer. Future Oncology, 2021, 17, 1889-1906.	1.1	0
99	Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. Journal of General Internal Medicine, 2021, , 1.	1.3	2
100	Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes. Cancer, 2021, 127, 3605-3613.	2.0	7
101	Framing Effects on Decision-Making for Diagnostic Genetic Testing: Results from a Randomized Trial. Genes, 2021, 12, 941.	1.0	3
102	Cancer genetic testing in marginalized groups during an era of evolving healthcare reform. Journal of Cancer Policy, 2021, 28, 100275.	0.6	10
103	Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. Cancer Science, 2021, 112, 3338-3348.	1.7	3
104	Disparities in Breast Cancer Associated With African American Identity. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e29-e46.	1.8	27
105	Clinical practice guidelines for risk assessment to identify women at high risk of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021. Chinese Medical Journal, 2021, 134, 1655-1657.	0.9	3
106	Association of Family History with the Development of Breast Cancer: A Cohort Study of 129,374 Women in KoGES Data. International Journal of Environmental Research and Public Health, 2021, 18, 6409.	1.2	5
107	A pitfall in targeted Sanger sequencing of BRCA splicing variants in at-risk individuals. Pathology Research and Practice, 2021, 222, 153456.	1.0	0
108	Cancer Health Assessments Reaching Many (CHARM): A clinical trial assessing a multimodal cancer genetics services delivery program and its impact on diverse populations. Contemporary Clinical Trials, 2021, 106, 106432.	0.8	19
109	REM Sleep Behavior Disorder as a Pathway to Dementia: If, When, How, What, and Why Should Physicians Disclose the Diagnosis and Risk for Dementia. Current Sleep Medicine Reports, 2021, 7, 57-64.	0.7	15
110	Oncologic Anthropology: An Interdisciplinary Approach to Understanding the Association Between Genetically Defined African Ancestry and Susceptibility for Triple Negative Breast Cancer. Current Breast Cancer Reports, 2021, 13, 247-258.	0.5	7
111	Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Breast Cancer, 2022, 29, 92-102.	1.3	2

#	Article	IF	Citations
112	Nanotechnology in Tumor Biomarker Detection: The Potential of Liganded Nanoclusters as Nonlinear Optical Contrast Agents for Molecular Diagnostics of Cancer. Cancers, 2021, 13, 4206.	1.7	27
113	Increasing referral of atâ€risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. Cancer, 2021, , .	2.0	5
114	Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials. EClinicalMedicine, 2021, 38, 101031.	3.2	2
115	Impact of a Breast Cancer Screening Algorithm on Early Detection. Journal for Nurse Practitioners, 2021, , .	0.4	2
116	What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12â€¯months after premenopausal risk-reducing salpingo-oophorectomy. Gynecologic Oncology, 2021, 162, 447-453.	0.6	9
117	Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. Gynecologic Oncology, 2021, 162, 506-516.	0.6	39
118	Characteristics and Experiences of Patients from a Community-Based and Consumer-Directed Hereditary Cancer Population Screening Initiative. Human Genetics and Genomics Advances, 2021, 3, 100055.	1.0	0
119	Management of breast cancer patients with BRCA gene mutations in Lebanon of the Middle East: perspectives and challenges. Hospital Practice (1995), 2021, , 1-5.	0.5	0
120	Clinical Implications of Combinatorial Pharmacogenomic Tests Based on Cytochrome P450 Variant Selection. Frontiers in Genetics, 2021, 12, 719671.	1.1	8
121	Design and user experience testing of a polygenic score report: a qualitative study of prospective users. BMC Medical Genomics, 2021, 14, 238.	0.7	29
122	The Need to Improve the Clinical Utility of Direct-to-Consumer Genetic Tests. JAMA - Journal of the American Medical Association, 2020, 323, 1443.	3.8	5
124	Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians. Cancer Prevention Research, 2021, 14, 205-214.	0.7	4
125	Mental Illness and BRCA1/2 Genetic Testing Intention Among Multiethnic Women Undergoing Screening Mammography. Oncology Nursing Forum, 2020, 47, E13-E24.	0.5	4
126	Effects of Marital Status on Prognosis in Women with Infiltrating Ductal Carcinoma of the Breast: A Real-World 1: 1 Propensity-Matched Study. Medical Science Monitor, 2020, 26, e923630.	0.5	6
127	How to manage BRCA mutation carriers?. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	6
128	NCCN Guidelines Insights: Survivorship, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1016-1023.	2.3	64
129	A Web-Based Tool to Automate Portions of Pretest Genetic Counseling for Inherited Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 841-847.	2.3	18
130	HistÃ³rico familiar para cÃ¢ncer de mama em mulheres: estudo populacional em Uberaba (MG) utilizando o Family History Screen-7. SaÃºde Em Debate, 2021, 45, 681-690.	0.1	0

#	Article	IF	Citations
131	USPSTF Approach to Addressing Sex and Gender When Making Recommendations for Clinical Preventive Services. JAMA - Journal of the American Medical Association, 2021, 326, 1953.	3.8	27
132	Multiple imputation with missing data indicators. Statistical Methods in Medical Research, 2021, 30, 2685-2700.	0.7	30
133	Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer. Familial Cancer, 2022, 21, 295-304.	0.9	15
134	Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies. Surgical Oncology Clinics of North America, 2022, 31, 109-126.	0.6	9
135	Identification of women at risk of hereditary breastâ€“ovarian cancer among participants in a population-based breast cancer screening. Familial Cancer, 2021, , 1.	0.9	1
136	Fertility Considerations for Reproductive-Aged Carriers of DeleteriousBRCAMutations: A Call for Early Intervention. JCO Oncology Practice, 2022, 18, 165-168.	1.4	4
137	Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA mutations: Unmet needs in Low- and Middle- Income Countries. The Journal of Breast Health, 2021, 18, 0-0.	0.4	1
138	A Breast Radiology Department-operated, Proactive Same-day Program Identifies Pathogenic Breast Cancer Mutations in Unaffected Women. Academic Radiology, 2020, , .	1.3	2
139	The Primary Prevention of Breast Cancer: Risk Assessment, Genetic Screening, Chemoprevention, and Modifiable Risk Factors. , 2020, , 275-296.		0
140	Hereditary Cancer Risk Using a Genetic Chatbot Before Routine Care Visits. Obstetrics and Gynecology, 2021, 138, 860-870.	1.2	37
141	Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. Breast Care, 2021, 16, 389-395.	0.8	0
142	Genetic Counseling in Hereditary Breast and Ovarian Cancer. , 2021, , 65-77.		0
143	Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomes. Journal of Telemedicine and Telecare, 2024, 30, 334-343.	1.4	2
144	Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer. Cancer Research and Treatment, 2022, 54, 1099-1110.	1.3	1
145	Decision thresholds with genetic testing. European Journal of Health Economics, 2021, , 1.	1.4	1
147	BRCA-Related Cancer Genetic Counseling is Indicated in Many Women Seeking Primary Care. Journal of the American Board of Family Medicine, 2020, 33, 885-893.	0.8	12
148	Survey on Physiciansâ€™ Knowledge and Training Needs in Genetic Counseling in Germany. Breast Care, 2021, 16, 389-395.	0.8	3
149	Self-rated family health history knowledge among All of Us program participants. Genetics in Medicine, 2022, 24, 955-961.	1.1	8

#	Article	IF	Citations
150	Automated Clinical Practice Guideline Recommendations for Hereditary Cancer Risk Using Chatbots and Ontologies: System Description. JMIR Cancer, 2022, 8, e29289.	0.9	3
151	Psychiatric symptoms in a Spanish sample with hereditary cancer risk. Journal of Community Genetics, 2022, , 1.	0.5	0
152	Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system. Hereditary Cancer in Clinical Practice, 2022, 20, 7.	0.6	7
153	Hereditary Breast and Ovarian Cancer. Obstetrics and Gynecology Clinics of North America, 2022, 49, 117-147.	0.7	3
154	Comparison of a Cancer Family History Collection and Risk Assessment Tool â€“ ItRunsInMyFamily â€“ with Risk Assessment by Health-Care Professionals. Public Health Genomics, 2022, 25, 80-88.	0.6	2
155	Hereditary breast cancer â€“ what we have learned in the last decade. Mastology, 0, 31, .	0.1	1
156	A universal probe system for low-abundance point mutation detection based on endonuclease IV. Analyst, The, 2022, 147, 1534-1539.	1.7	1
157	Psychosocial outcome and health behaviour intent of breast cancer patients with BRCA1/2 and PALB2 pathogenic variants unselected by a priori risk. PLoS ONE, 2022, 17, e0263675.	1.1	0
158	Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers. Annals of Surgical Oncology, 2022, 29, 3578-3590.	0.7	9
160	Factors Associated with Mammography Screening Choices by Women Aged 40â€“49 at Average Risk. Journal of Women's Health, 2022, 31, 1120-1126.	1.5	5
161	Hereditary gynecologic tumors and precision cancer medicine. Journal of Obstetrics and Gynaecology Research, 2022, 48, 1076-1090.	0.6	0
162	IPRS: Leveraging Gene-Environment Interaction to Reconstruct Polygenic Risk Score. Frontiers in Genetics, 2022, 13, 801397.	1.1	4
163	Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access. Genetics in Medicine, 2022, 24, 1196-1205.	1.1	6
164	Predicting breast cancer risk in a racially diverse, communityâ€based sample of potentially highâ€risk women. Cancer Medicine, 2022, 11, 4043-4052.	1.3	4
165	Can Social Media Be Used as a Community-Building and Support Tool among Jewish Women Impacted by Breast and Ovarian Cancer? An Evidence-Based Observational Report. Healthcare (Switzerland), 2022, 10, 51.	1.0	2
166	Chronic Stress Effects on Tumor: Pathway and Mechanism. Frontiers in Oncology, 2021, 11, 738252.	1.3	28
167	Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More Than 10 Years. Cancers, 2021, 13, 6254.	1.7	5
168	Health Economics Research in Primary Prevention of Cancer: Assessment, Current Challenges, and Future Directions. Journal of the National Cancer Institute Monographs, 2022, 2022, 28-41.	0.9	4

#	Article	IF	Citations
169	Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. BioMed Research International, 2022, 2022, 1-16.	0.9	156
170	Prevalence of Americans reporting a family history of cancer indicative of increased cancer risk: Estimates from the 2015 National Health Interview Survey. Preventive Medicine, 2022, 159, 107062.	1.6	5
171	Principles of molecular testing for hereditary cancer. Genes Chromosomes and Cancer, 2022, 61, 356-381.	1.5	5
172	Histological and Immunohistochemical Characteristics for Hereditary Breast Cancer Risk in a Cohort of Brazilian Women. Revista Brasileira De Ginecologia E Obstetricia, 2022, 44, 761-770.	0.3	1
173	Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 471-482.	1.8	19
174	Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record. Frontiers in Genetics, 2022, 13, 866169.	1.1	4
175	Changes in Sex Steroids and Relation With Menopausal Complaints in Women Undergoing Risk-reducing Salpingo-oophorectomy. Journal of the Endocrine Society, 2022, 6, bvac069.	0.1	5
176	Attitudes and interest in incorporating BRCA1/2 cancer susceptibility testing into reproductive carrier screening for Ashkenazi Jewish men and women. Journal of Community Genetics, 2022, , 1.	0.5	2
177	Familial risk of epithelial ovarian cancer after accounting for gynaecological surgery: a population-based study. Journal of Medical Genetics, 2023, 60, 119-127.	1.5	2
178	Report from an NCI Roundtable: Cancer Prevention in Primary Care. Cancer Prevention Research, 2022, 15, 273-278.	0.7	1
179	Socioeconomic Status and Interest in Genetic Testing in a US-Based Sample. Healthcare (Switzerland), 2022, 10, 880.	1.0	7
181	Healthcare Predictors of Information Dissemination About Genetic Risks. Cancer Control, 2022, 29, 107327482211046.	0.7	1
182	Literacy-adapted, electronic family history assessment for genetics referral in primary care: patient user insights from qualitative interviews. Hereditary Cancer in Clinical Practice, 2022, 20, .	0.6	2
183	Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 2326.	3.8	63
184	Medicaid Expansions: Probing Medicaidâ€™s Filling of the Cancer Genetic Testing and Screening Space. Healthcare (Switzerland), 2022, 10, 1066.	1.0	3
185	Preoperative Evaluation and Preparation for Ovarian Tissue Transplant Surgery. , 2022, , 109-115.		1
186	Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006â€“2016. BMC Women's Health, 2022, 22, .	0.8	0
187	Riskâ€reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system. Cancer, 2022, 128, 3090-3098.	2.0	2

#	Article	IF	Citations
188	Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system. Breast Cancer Research and Treatment, 2022, 195, 153-160.	1.1	4
189	Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes. International Journal of Environmental Research and Public Health, 2022, 19, 8113.	1.2	48
190	Womenâ€™s health update: A literature review impacting primary care. Cleveland Clinic Journal of Medicine, 2022, 89, 373-381.	0.6	0
192	Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care. JAMA Network Open, 2022, 5, e2222092.	2.8	10
193	Motivational interviewing for genetic counseling: A unified framework for persuasive and equipoise conversations. Journal of Genetic Counseling, 2022, 31, 1020-1031.	0.9	7
194	Attitudes towards and sociodemographic determinants of genetic test usage in the <scp>USA</scp>; data from the Health Information National Trend Survey, 2020. Journal of Genetic Counseling, 2023, 32, 57-67.	0.9	2
195	Hereditary Breast and Ovarian Cancer Genetic Risk: Screening and Treatment Among Transgender and Gender Diverse Patients. , 2022, 26, 30-38.		2
196	Association between Health Insurance Type and Genetic Testing and/or Counseling for Breast and Ovarian Cancer. Journal of Personalized Medicine, 2022, 12, 1263.	1.1	2
197	Decoding Breast Cancer Metabolism: Hunting BRCA Mutations by Raman Spectroscopy. Photochem, 2022, 2, 752-764.	1.3	2
198	Identification of cuproptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer. Frontiers in Immunology, 0, 13, .	2.2	29
199	Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies. Molecular Therapy - Oncolytics, 2022, 26, 347-359.	2.0	2
200	Targeted molecular profiling of epithelial ovarian cancer from Italian BRCA wild-type patients with a BRCA and PARP pathways gene panel. Experimental and Molecular Pathology, 2022, 128, 104833.	0.9	2
201	Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer. Annals of Laboratory Medicine, 2023, 43, 73-81.	1.2	3
202	Breast Cancer in Asia: Incidence, Mortality, Early Detection, Mammography Programs, and Risk-Based Screening Initiatives. Cancers, 2022, 14, 4218.	1.7	25
203	Surgical Management for Transposed Ovarian Recurrence of Cervical Cancer: A Systematic Review with Our Experience. Current Oncology, 2022, 29, 7158-7170.	0.9	0
204	Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer. JAMA Network Open, 2022, 5, e2232787.	2.8	10
205	Barriers to breast cancer screening in Atlanta, GA: results from the Pink Panel survey at faith-based institutions. Cancer Causes and Control, 2022, 33, 1465-1472.	0.8	1
206	The Role of Race and Insurance Status in Access to Genetic Counseling and Testing Among High-Risk Breast Cancer Patients. Oncologist, 2022, 27, 832-838.	1.9	11

#	Article	IF	Citations
207	State-Level Variation In Low-Value Care For Commercially Insured And Medicare Advantage Populations. Health Affairs, 2022, 41, 1281-1290.	2.5	2
208	Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy. International Journal of Environmental Research and Public Health, 2022, 19, 12057.	1.2	17
209	Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients. Annals of Surgical Oncology, 2023, 30, 1017-1025.	0.7	9
210	UBE2T regulates epithelialâ€“mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer. Journal of Ovarian Research, 2022, 15, .	1.3	3
211	Risk Assessment and Prevention Strategies for Hereditary Gynecological Cancers. Comprehensive Gynecology and Obstetrics, 2022, , 87-113.	0.0	0
212	Ovarian Cancer Screening and Early Detection. , 2022, , 9-25.		1
213	Family Health History Day is Thanksgiving Day. Journal of the American Pharmacists Association: JAPhA, 2022, , .	0.7	0
214	Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by an Expert Group from Middle East and North Africa Region. Current Women's Health Reviews, 2022, 19, .	0.1	0
215	Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications. Current Oncology Reports, 2022, 24, 1791-1800.	1.8	1
216	Hereditary ovarian cancer. Siberian Journal of Oncology, 2022, 21, 123-134.	0.1	0
217	Genetics of Breast Cancer. Surgical Clinics of North America, 2022, , .	0.5	5
218	Testing a deliberative democracy method with citizens of African ancestry to weigh pros and cons of targeted screening for hereditary breast and ovarian cancer risk. Frontiers in Public Health, 0, 10, .	1.3	4
219	Testing for Inherited Susceptibility to Breast Cancer. Hematology/Oncology Clinics of North America, 2023, 37, 17-31.	0.9	0
221	Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience. Diagnostics, 2022, 12, 3054.	1.3	0
222	All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits. British Journal of Cancer, 2023, 128, 638-646.	2.9	3
223	Understanding cancer genetic risk assessment motivations in a remote tailored risk communication and navigation intervention randomized controlled trial. Health Psychology and Behavioral Medicine, 2022, 10, 1190-1215.	0.8	0
224	The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert Review of Pharmacoeconomics and Outcomes Research, 2023, 23, 309-316.	0.7	5
225	Gynecologic imaging. , 2023, , 313-331.		0

#	Article	IF	Citations
226	Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment. Expert Review of Pharmacoeconomics and Outcomes Research, 2023, 23, 297-307.	0.7	0
227	Factors Influencing Residual Glandular Breast Tissue after Risk-Reducing Mastectomy in Genetically Predisposed Individuals Detected by MRI Mammography. Cancers, 2023, 15, 829.	1.7	2
229	Liquid biopsy: a right tool in a right context?. , 2023, , 31-45.		0
230	Results of a randomized controlled trial of a decision support intervention for disclosing maternal BRCA genetic test results to children and adolescents. PEC Innovation, 2023, 2, 100129.	0.3	1
231	Navigating the uncertainty of precision cancer screening: The role of shared decision-making. PEC Innovation, 2023, 2, 100127.	0.3	1
232	Impact of Breast Cancer and Germline BRCA Pathogenic Variants on Fertility Preservation in Young Women. Life, 2023, 13, 930.	1.1	1
233	Web-based tool for cancer family history collection: A prospective randomized controlled trial. Gynecologic Oncology, 2023, 173, 22-30.	0.6	4
234	Twenty years of capacity building across the cancer prevention and control research network. Cancer Causes and Control, 0, , .	0.8	1
236	Hereditary Womenâ€™s Cancer: Management and Risk-Reducing Surgery. Medicina (Lithuania), 2023, 59, 300.	0.8	4
237	Prediction of carrying a BRCA1 or BRCA2 mutation. Annals of Translational Medicine, 2023, 11, 271-271.	0.7	1
238	Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception. Breast Cancer Research and Treatment, 2023, 200, 63-72.	1.1	2
239	Cost-Effectiveness of Genetic Testing Strategies for Breast Cancer. , 2023, , 113-126.		0
240	Genetic Considerations in the Locoregional Management of Breast Cancer: a Review of Current Evidence. Current Breast Cancer Reports, 2023, 15, 48-57.	0.5	0
241	Patients' attitudes regarding genetic counseling before germline BRCA1/2 pathogenic variants testing in Taiwan: AÂ<scp>singleâ€country</scp>, <scp>multiâ€center</scp>, <scp>patientâ€reported</scp> outcome study. Journal of Genetic Counseling, 2023, 32, 788-797.	0.9	1
242	Variant curation and interpretation in hereditary cancer genes: An institutional experience in Latin America. Molecular Genetics & Genomic Medicine, 0, , .	0.6	1
243	Hereditary Breast Cancer Non-CDH1 Associated. , 2023, , 361-386.		0
245	Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study. Genome Medicine, 2023, 15, .	3.6	3
246	Advancing health equity: A qualitative study assessing barriers and facilitators of implementing hereditary breast and ovarian cancer risk screening tools in communityâ€based organizations. Journal of Genetic Counseling, 2023, 32, 965-981.	0.9	3

#	Article	IF	Citations
247	An Overview of the Use of Precision Population Medicine in Cancer Care: First of a Series. Cureus, 2023, , .	0.2	1
252	Population health management. , 2023, , 715-725.		0
282	Utilization of the microbiome in personalized medicine. Nature Reviews Microbiology, 0, , .	13.6	5
283	Handling Germline Findings in Ovarian Cancer Cases. , 2023, , 129-141.		0
289	Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection. Cancer Treatment and Research, 2023, , 63-88.	0.2	0
293	Gold nanomaterials: important vectors in biosensing of breast cancer biomarkers. Analytical and Bioanalytical Chemistry, 0, , .	1.9	0
296	The Molecular Classification of Ovarian Cancer and Implication for Treatment. , 2023, , 285-315.		0